Lexaria Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Lexaria Bioscience Corp
LEXX Stock  USD 2.13  0.02  0.93%   
Lexaria Bioscience financial statements provide useful quarterly and yearly information to potential Lexaria Bioscience Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lexaria Bioscience financial statements helps investors assess Lexaria Bioscience's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lexaria Bioscience's valuation are summarized below:
Gross Profit
183.6 K
Market Capitalization
37.5 M
Enterprise Value Revenue
70.9463
Revenue
411 K
Earnings Share
(0.44)
We have found one hundred twenty available fundamental ratios for Lexaria Bioscience, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Lexaria Bioscience last-minute market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 120.9 M in 2024. Enterprise Value is likely to rise to about 122.2 M in 2024

Lexaria Bioscience Total Revenue

400,398

Check Lexaria Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexaria Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 132.7 K, Interest Expense of 107.8 K or Other Operating Expenses of 8.2 M, as well as many indicators such as Price To Sales Ratio of 110, Dividend Yield of 0.0 or PTB Ratio of 57.61. Lexaria financial statements analysis is a perfect complement when working with Lexaria Bioscience Valuation or Volatility modules.
  
Check out the analysis of Lexaria Bioscience Correlation against competitors.

Lexaria Bioscience Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4.1 M3.5 M3.6 M
Slightly volatile
Other Current Liabilities289.7 K275.9 K106.1 K
Slightly volatile
Total Current Liabilities472.9 K241 K370.5 K
Slightly volatile
Total Stockholder Equity3.4 M3.5 M3.3 M
Slightly volatile
Property Plant And Equipment Net360.5 K379.4 K704.4 K
Slightly volatile
Accounts Payable271.7 K258.8 K89.8 K
Slightly volatile
Cash1.8 M1.6 M2 M
Slightly volatile
Non Current Assets Total1.3 M795.8 K944.9 K
Pretty Stable
Cash And Short Term Investments1.8 M1.7 M2.1 M
Slightly volatile
Common Stock Total Equity95.1 K90.6 K60.3 K
Slightly volatile
Common Stock Shares Outstanding8 M7.6 M4.8 M
Pretty Stable
Liabilities And Stockholders Equity4.1 M3.5 M3.6 M
Slightly volatile
Non Current Liabilities Total216.6 K122.6 K66.7 K
Slightly volatile
Other Current Assets660.2 K628.8 K261.9 K
Slightly volatile
Other Stockholder Equity58.9 M56.1 M26.6 M
Slightly volatile
Total Liabilities556.3 K363.5 K416 K
Pretty Stable
Property Plant And Equipment Gross1.4 M807.1 K869.8 K
Pretty Stable
Total Current Assets2.2 M2.5 M2.6 M
Slightly volatile
Common Stock8.8 K9.3 K35.4 K
Pretty Stable
Short and Long Term Debt Total140.2 K147.6 K417.7 K
Slightly volatile
Net Receivables166 K201.5 K170.8 K
Slightly volatile
Short Term Debt23.8 K25 K357.9 K
Slightly volatile
Intangible Assets558.6 K532 K227.5 K
Slightly volatile
Net Tangible Assets5.5 M8.6 M4.6 M
Slightly volatile
Net Invested Capital5.4 M3.5 M4.1 M
Slightly volatile
Net Working Capital2.1 M2.2 M3.3 M
Pretty Stable
Property Plant Equipment372.5 K423.1 K213.8 K
Slightly volatile
Short Term Investments256.8 K144.5 K124.9 K
Slightly volatile
Capital Stock6.9 K7.3 K53.8 K
Slightly volatile
Long Term Debt24.5 K27.6 K30.1 K
Slightly volatile
Capital Lease Obligations117.9 K188.6 K124.3 K
Very volatile
Short and Long Term Debt6.3 K7.1 K7.8 K
Slightly volatile

Lexaria Bioscience Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses8.2 M7.8 M4.1 M
Slightly volatile
Total Operating Expenses8.1 M7.7 M3.9 M
Slightly volatile
Total Revenue400.4 K203.6 K436.1 K
Slightly volatile
Cost Of Revenue26.9 K28.4 K203.6 K
Slightly volatile
Selling General Administrative2.4 M3.5 M2.7 M
Slightly volatile
Selling And Marketing Expenses154.5 K234.9 K194.8 K
Slightly volatile
Research Development4.4 M4.2 M1.2 M
Slightly volatile
Reconciled Depreciation96.1 K167.2 K58.9 K
Slightly volatile

Lexaria Bioscience Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures145 K152.6 K153 K
Very volatile
End Period Cash Flow1.8 M1.6 M2 M
Slightly volatile
Begin Period Cash Flow7 M6.7 M2.7 M
Slightly volatile
Depreciation87.5 K130.9 K83.8 K
Pretty Stable
Other Non Cash Items461.6 K609.9 K439.4 K
Slightly volatile
Stock Based Compensation186.1 K195.9 K516.5 K
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio110105185
Slightly volatile
PTB Ratio57.6154.870113.2766
Slightly volatile
Days Sales Outstanding25.0326.3466473
Slightly volatile
Book Value Per Share0.07760.08160.777
Pretty Stable
Average Payables38.1 K68.7 K59.1 K
Pretty Stable
Stock Based Compensation To Revenue0.710.7487.2908
Slightly volatile
Capex To Depreciation0.760.799117.0387
Slightly volatile
PB Ratio57.6154.870113.2766
Slightly volatile
EV To Sales111106173
Slightly volatile
Payables Turnover9.68.52.3046
Slightly volatile
Sales General And Administrative To Revenue1.11.160242.5564
Slightly volatile
Research And Ddevelopement To Revenue15.3214.597.3738
Pretty Stable
Capex To Revenue0.07930.08351.2335
Slightly volatile
Cash Per Share0.00240.00250.5346
Pretty Stable
Days Payables Outstanding40.7942.941464
Very volatile
Intangibles To Total Assets0.140.150.0773
Slightly volatile
Net Debt To EBITDA4.334.12040.9547
Slightly volatile
Current Ratio0.09820.103419.2618
Very volatile
Tangible Book Value Per Share0.07760.08160.7294
Pretty Stable
Receivables Turnover14.5513.85382.72
Slightly volatile
Graham Number0.350.36574.2697
Pretty Stable
Shareholders Equity Per Share0.07760.08160.831
Very volatile
Debt To Equity0.730.70.2072
Slightly volatile
Capex Per Share0.00340.00360.0384
Very volatile
Average Receivables194.3 K185.1 K170.5 K
Slightly volatile
Revenue Per Share0.04060.04270.0566
Slightly volatile
Interest Debt Per Share0.06560.06910.0261
Slightly volatile
Debt To Assets0.220.410.1009
Slightly volatile
Operating Cycle25.0326.34661.5 K
Slightly volatile
Price Book Value Ratio57.6154.870113.2766
Slightly volatile
Days Of Payables Outstanding40.7942.941464
Very volatile
Company Equity Multiplier1.561.70251.1474
Slightly volatile
Long Term Debt To Capitalization0.130.250.1299
Pretty Stable
Total Debt To Capitalization0.230.440.1314
Pretty Stable
Debt Equity Ratio0.730.70.2072
Slightly volatile
Quick Ratio0.09820.103417.9369
Pretty Stable
Net Income Per E B T1.161.00.9411
Slightly volatile
Cash Ratio0.0440.046313.9891
Pretty Stable
Days Of Sales Outstanding25.0326.3466473
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.680.71460.9955
Slightly volatile
Price To Book Ratio57.6154.870113.2766
Slightly volatile
Fixed Asset Turnover0.30.320232.5135
Very volatile
Debt Ratio0.220.410.1009
Slightly volatile
Price Sales Ratio110105185
Slightly volatile
Asset Turnover0.320.30710.0922
Slightly volatile
Price Fair Value57.6154.870113.2766
Slightly volatile

Lexaria Bioscience Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap120.9 M115.2 M24.5 M
Slightly volatile
Enterprise Value122.2 M116.4 M22.9 M
Slightly volatile

Lexaria Fundamental Market Drivers

Cash And Short Term Investments1.5 M

Lexaria Upcoming Events

12th of April 2024
Upcoming Quarterly Report
View
12th of July 2024
Next Financial Report
View
29th of February 2024
Next Fiscal Quarter End
View
19th of November 2024
Next Fiscal Year End
View
30th of November 2023
Last Quarter Report
View
31st of August 2023
Last Financial Announcement
View

About Lexaria Bioscience Financial Statements

Lexaria Bioscience investors use historical fundamental indicators, such as Lexaria Bioscience's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexaria Bioscience. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-202.5 K-192.4 K
Total Revenue203.6 K400.4 K
Cost Of Revenue28.4 K26.9 K
Stock Based Compensation To Revenue 0.75  0.71 
Sales General And Administrative To Revenue 1.16  1.10 
Research And Ddevelopement To Revenue 14.59  15.32 
Capex To Revenue 0.08  0.08 
Revenue Per Share 0.04  0.04 
Ebit Per Revenue 0.27  0.28 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY